Related Experiment Video
Updated: Jun 6, 2026
Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest
Published on: May 26, 2023
Coagulation considerations for infants and children undergoing cardiopulmonary bypass
Michael P Eaton1, Ellen M Iannoli
1Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. Michael_Eaton@urmc.rochester.edu
Insights
Pediatric cardiac surgery with cardiopulmonary bypass increases bleeding risks due to immature coagulation. Novel anticoagulation strategies are needed to improve outcomes for these vulnerable patients.
Area of Science:
- Cardiovascular Surgery
- Pediatric Cardiology
- Hematology
Background:
- Cardiopulmonary bypass (CPB) in pediatric cardiac surgery presents significant pathophysiologic challenges.
- Pediatric patients face heightened risks of bleeding and poor outcomes due to CPB, linked to hematologic immaturity and congenital heart defects.
- Standard anticoagulation during CPB is insufficient, leading to continuous coagulation factor consumption and thrombin generation.
Purpose of the Study:
- To highlight the unique coagulopathic challenges in pediatric cardiac surgery.
- To evaluate the limitations of conventional anticoagulation monitoring during CPB.
- To explore emerging therapies for optimizing anticoagulation and reducing complications.
Main Methods:
- Review of existing literature on coagulation during pediatric CPB.
- Analysis of factors contributing to bleeding risks in pediatric cardiac surgery.
- Discussion of current and novel anticoagulation monitoring and therapeutic approaches.
Main Results:
- Pediatric patients exhibit increased susceptibility to CPB-induced coagulopathy, inversely proportional to weight.
- Conventional anticoagulation monitoring inadequately reflects thrombin generation during bypass.
- Continuous consumption of coagulation factors occurs throughout the CPB procedure.
Conclusions:
- Pediatric cardiac surgery patients are at high risk for bleeding complications due to CPB-related coagulopathy.
- Current anticoagulation management and monitoring during CPB are suboptimal for pediatric populations.
- Emerging anticoagulation therapies show promise for mitigating bleeding and improving outcomes in pediatric congenital heart surgery.
Abstract:
Cardiac surgery involving cardiopulmonary bypass imposes a significant pathophysiologic burden on patients. Pediatric patients are especially predisposed to the adverse effects of surgery and bypass on the coagulation system, with resultant bleeding, transfusion, and poor outcomes. These risks accrue to pediatric patients in inverse proportion to their weight and are attributable to hematologic immaturity, coagulation defects associated with congenital heart disease, bypass equipment, and the nature of congenital heart surgery. Standard anticoagulation does not completely inhibit thrombin generation, and continuous consumption of coagulation factor continues throughout bypass. Conventional measurements of anticoagulation during bypass poorly reflect this incomplete anticoagulation, and alternate methods may improve anticoagulant therapy. Emerging therapies for blocking the effects of bypass on the coagulation system hold promise for decreasing bleeding and related complications, and improving outcomes in congenital heart surgery.
Related Concept Videos
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
01:28Cardiac Catheterization I: Pre-Procedure Overview